Loading…
This event has ended. Visit the official site or create your own event on Sched.
The Virtual 16th Annual Meeting of ISMPP is June 16-18, 2020. All times are ET. REGISTER NOW! Fees are $720 USD. Registration ends June 5, 2020.
Register 10 attendees from the same company and receive a 10% discount AND your company will be recognized as a Champion Sponsor! Contact ismpp@ismpp.org to take advantage of this great offer!
Back To Schedule
Thursday, June 18 • 3:00pm - 4:00pm
Watch On Demand: Mapping and Navigating the New Frontier of Gene Therapy Publication Planning

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Join us for an interactive panel discussion among industry publications experts around the considerations and challenges for publication planning in support of one of the most rapidly evolving areas of therapeutic development – gene therapies.  Communications around gene therapies may require adjustment from conventional experience regarding timing and scope of publication plans. Panelists will educate on similarities and differences regarding publication planning for conventional therapies vs those for gene therapies and how to best navigate the different requirements.
This session qualifies for ISMPP CMPP credit
This session qualifies for pharmacy CE credit

Speakers
avatar for Robin LeWinter

Robin LeWinter

Senior Director, Medical Communications, Orchard Therapeutics
Robin LeWinter obtained her PhD in Neuroscience from the University of California, San Francisco, followed by a post-doc at SRI, International. Robin has over 15 years of experience in the field of Medical Communications and Publications at several small and mid-sized pharmaceutical... Read More →
avatar for Eugene Tombler

Eugene Tombler

Medical Insights Director, CMC - Connect
Gene Tombler has worked in medical communications and continuing education in various roles from medical writer, executive medical director and vice president for over sixteen years. He has served three years in his current position as the Medical Insights Director of CMC-Connect... Read More →
avatar for Kate Lewis

Kate Lewis

VP, Program Lead, Beta-Thalassemia
Kate Lewis, MA is vice president and program lead at bluebird bio, a leading developer of gene therapies for severe genetic diseases and cancer. She currently leads bluebird’s beta-thalassemia gene therapy program, developing betibeglogene autotemcel, an ex vivo, lentiviral-vector-based... Read More →

Thursday June 18, 2020 3:00pm - 4:00pm EDT

Attendees (41)